Research Reports

153 Illicit Drug Use in the Flemish Nightlife Scene between 2003 and 2009
Van Havere, T.; Lammertyn, J.; Vanderplasschen, W. (Ghent); Bellis, M. (Liverpool); Rosiers, J. (Brussels); Broekaert, E. (Ghent)

161 Association of a Genetic Polymorphism of the Alcohol-Metabolizing Enzyme ADH1C with Alcohol Dependence: Results of a Case-Control Study
Kortunay, S.; Köeler, A.; Özdemir, F.; Atalay, E.O. (Denizli)

167 Co-Occurrence of Addictive Behaviours: Personality Factors Related to Substance Use, Gambling and Computer Gaming
Walther, B.; Morgenstern, M.; Hanewinkel, R. (Kiel)

175 On-Site Drugs of Abuse Urinary Screening Tests for the Management of Opiate-Addicted Patients: A Survey among French General Practitioners

184 Differential Profiles of Crack Users in Respondent-Driven and Institutional Samples: A Three-Site Comparison
Oteo Pérez, A.; Benschop, A.; Korf, D.J. (Amsterdam)

193 Validation of the Cannabis Abuse Screening Test in a Sample of Cannabis Inpatients
Legleye, S. (Paris/Saint-Denis); Kraus, L. (Munich/Stockholm); Piontek, D. (Munich); Phan, O.; Jouanne, C. (Paris)

201 Role of Two Clusters of Male Alcoholics in Treatment Retention
Baltieri, D.A.; Corrêa Filho, J.M. (São Paulo)
The neurobiological approach to behavior and mental disorders

Neuropsychobiology

International Journal of Experimental and Clinical Research in Biological Psychiatry, Psychoneuropharmacology, Biological Psychology/Pharmacology and Pharmacoelectronophysiology

Selected contributions

- Novel Schizophrenia Risk Gene-TEF-1 Influences Verbal Learning and Memory Functioning in Schizophrenia Patients: Sennett, L. (Basel), et al.
- Lack of Association between Testosterone and Suicide Attempts: Poppo, W.; Reber, A.; Bailer, C. (Bern); Schmid, R. (Dresden/Berlin); Pfennig, A.; Sasse, J. (Dresden/Berlin); Anderer, P. (Bologna); Bellodi, L. (Dresden/Berlin); Brüninghaus, A.; Porz, R. (Bologna);

More information at www.karger.com/nps

- Pay-per-View and Subscribe
- Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Modern medicine is now in a position to make advanced progresses that chart the entire course of illness and recovery. Paradoxically, this is coupled with a new dimension of uncertainty for the patient, i.e. coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take in this publication, renowned experts in this field discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epidemiological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g. the promise of anti-aging and the challenges that will likely accompany this.

This publication aims to bridge the different fields with an area addressing the challenges facing and encouraging dialogue. It will be of interest to all readers who deal with ethical problems of prognosis, particularly in medicine, as well as to theologians and sociologists.

Contents

- Introduction: Pfleiderer, G.; Battegay, M.; Lindpaintner, K.
- Medical Perspectives
  - Evolving Therapy and Prognosis in HSCT -- How Knowing One’s Medical Fate in Advance Can Change Dramatically: Battegay, M.
  - Related to Human Cognition: Is Personalization Feasible and Desirable?: Manji, H.K.
- Ethical and Juridical Perspectives
  - Predictive Medicine – Changes in Our View of Ourselves and Others: Birnbacher, D.
  - Current Challenges for the Law: Disclosure Dilemmas in Predictive Medicine: Dorn, B.S.

Order Form

- Payment:
  - Please charge to my credit card
  - Please send:
    - Check enclosed
    - Money order
    - Visa
    - MasterCard
    - American Express
    - Diners

Bridging the gaps between medicine, ethics, philosophy and religion

Modern medicine is now in a position to make advanced progresses that chart the entire course of illness and recovery. Paradoxically, this is coupled with a new dimension of uncertainty for the patient, i.e. coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take in this publication, renowned experts in this field discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epidemiological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g. the promise of anti-aging and the challenges that will likely accompany this.

This publication aims to bridge the different fields with an area addressing the challenges facing and encouraging dialogue. It will be of interest to all readers who deal with ethical problems of prognosis, particularly in medicine, as well as to theologians and sociologists.
Submission
Manuscripts written in English are considered and should be submitted online at:
www.karger.com/ear
If you wish to contact the Editorial Office directly, please mail to:
ear@karger.ch

Blind Review
A list of all authors and their institutes and affiliations as well as the exact postal address of the corresponding author complete with postal code, telephone, fax number and e-mail address should be supplied as a separate document to ensure anonymous reviewing.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘European Addiction Research’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Short Communications
In addition to regular papers, a section of the journal will publish brief communications of important findings, in which illustrative material should be limited. Such notes should include a brief summary and key words, the body of the report (without any subdivisions), brief acknowledgment, and a few selected references. The general style and submission procedures outlined above apply to the short communication.

Arrangement
**Title page:** In the accepted version, the first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

**Full address:** In the accepted version, the exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

**Key words:** Please supply 3–10 key words in English that reflect the content of the paper.

**Abstract:** Each paper needs an abstract of up to 10 lines.

**Footnotes:** Avoid footnotes.

**Tables and illustrations:** Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, the latter also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. R/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–223 mm or provide crop marks. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–223 mm or provide crop marks. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–223 mm or provide crop marks.

**Color illustrations**

**Online edition:** Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

**Print edition:** Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

**References:** In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

**Examples**

(a) Papers published in periodicals:


(b) Papers published only with DOI numbers:


(c) Monographs:


(d) Edited books:


**Reference Management Software:** Use of EndNote is recommended for easy management and formatting of citations and reference lists.

**Digital Object Identifier (DOI)**

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

**Supplementary Material**

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpg).

**Short Communications**

In addition to regular papers, a section of the journal will publish brief communications of important findings, in which illustrative material should be limited. Such notes should include a brief summary and key words, the body of the report (without any subdivisions), brief acknowledgment, and a few selected references. The general style and submission procedures outlined above apply to the short communication.

**Page Charges**

There are no page charges for papers of 5 or fewer printed pages. This is equivalent to approx. 13 manuscript pages, or a total of approx. 25,000 strokes or less in case of tables and illustrations. Each additional complete or partial page is charged to the author at CHF 325.–.

**Author’s Choice**

Karger’s Author’s ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

**NIH-Funded Research**

The U.S. National Institutes of Health (NIH) mandates that NIH-funded research be archived in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s ChoiceTM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/policy.htm.

**Self-Archiving**

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s ChoiceTM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

**Proofs**

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

**Reprints**

Orders and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

**Karger**

© 2012 S. Karger AG, Basel
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

The Guidelines for Authors are available at:
www.karger.com/ear_Guidelines
The American Academy of Addiction Psychiatry's (AAAP) 23rd Annual Meeting and Symposium will be held at the Turnberry Isle Hotel Miami, December 6-9, 2012. The conference provides physicians and allied health professionals who treat patients with substance use and mental health disorders, the latest scientific developments in Addiction Psychiatry and Addiction Medicine. The meeting is structured to encourage interaction among clinicians from various disciplines, approaches, and settings. Meeting events include symposia, workshops, poster sessions showcasing new research in the field, Breakfast for Trainees, Discussion with the Experts, and a Case Conference with expert discussion.

What is AAAP?

The American Academy of Addiction Psychiatry is a professional membership organization founded in 1985 with approximately 1,000 members in the United States and around the world. Membership consists of psychiatrists who treat patients with addictive disorders and their families, faculty at academic institutions engaged in Addiction Psychiatry research and teaching, medical students, residents and fellows, and non-psychiatrist professionals who are making a contribution to the field of Addiction Psychiatry.

AAAP Mission Statement

- Promote high quality evidence-based screening, assessment and treatment for substance use and co-occurring mental disorders.
- Translate and disseminate evidence-based research to clinical practice and public policy.
- Strengthen Addiction Psychiatry specialty training and foster careers in Addiction Psychiatry.
- Provide evidence-based addiction education to health care trainees and health professionals to enhance patient care and promote recovery.
- Educate the public and influence public policy for the safe and humane treatment of those with substance use disorders.
- Promote prevention and enhance addiction treatment and recovery across the life span.
- Promote research on the etiology, prevention, identification and treatment of substance use and related disorders.

REGISTRATION OPENS JULY 1, 2012

For more information please visit www.aaap.org or email annualmeeting@aaap.org.

400 Massasoit Avenue, Suite 307, East Providence, RI 02914
Phone: (401) 524-3076 ~ Fax: (401) 272-0922
www.aaap.org
Contents

See the journal website for contents
‘A collection of extraordinary essays’

GOTTFRID SCHATZ

A MATTER OF WONDER

What Biology Reveals about Us, Our World, and Our Dreams

Where do we come from? Is our destiny determined by the genes we inherit? In this book Gottfried Schatz, the world-renowned biochemist and co-discoverer of mitochondrial DNA, gives lucid – albeit often surprising – answers to universal questions and takes the reader on a fascinating journey of discovery across the boundaries of scientific disciplines. With passion and a keen sense of wonder he draws on philosophy, cultural history and art to formulate his reflections on the mysteries of life. His essays will appeal not only to scientists but to all inquisitive minds, regardless of educational and professional background.

More information and sample essays at www.karger.com/schatz
Psychopathology is a record of research centred on findings, concepts, and diagnostic categories of clinical and experimental psychopathology. Studies published are designed to improve and deepen the knowledge and understanding of the pathogenesis and nature of psychopathological symptoms and psychological dysfunctions. Furthermore, the validity and reliability of concepts applied in the neurosciences of mental functions are evaluated in order to closely bring together mind and the brain. Major topics of the journal are trajectories between biological processes on the one hand and psychological dysfunction on the other including a developmental perspective and a special interest on findings from neurosciences that can help us to better understand a subject’s inner experiences and interpersonal behavior. Descriptive psychopathology, experimental psychopathology, neuropsychology, epidemiology, transcultural psychiatry as well as philosophy-based phenomenology contribute to this field. Other important aspects include interrelationships between concepts of dysfunction and the influence of therapy, i.e. salutogenetic mechanisms.

Selected contributions
Contrasting Monosymptomatic Patients with Hallucinations and Delusions in First-Episode Psychosis Patients: A Five-Year Longitudinal Follow-Up Study: Evensen, J.; Rassberg, J.J. (Oslo); Haahr, U. (Roskilde); ten Velden Hegelstad, W.; Joa, I.; Johannessen, J.O.; Langeveld, H.; Larsen, T.K. (Stavanger/Bergen); Melle, I.; Opjordsmoen, S.; Rund, B. (Oslo); Simonsen, E. (Roskilde); Sundet, K.; Voglum, P.; Friis, S. (Oslo); McGlashan, T. (New Haven, Conn.)
Pretense, Social Cognition and Self-Knowledge in Autism: Varpa, S. (Oulu/Heidelberg)
Prenatal Stress: Course and Interrelation of Emotional and Physiological Stress Measures: Rothenberger, S.E.; Moehler, E.; Reck, C.; Resch, F. (Heidelberg)
Performance during Face Processing Differentiates Schizophrenia Patients with Delusional Misidentifications: Walther, S.; Federspiel, A.; Horn, H.; Wirth, M.; Bianchi, P.; Strik, W.; Müller, T.J. (Bern)
Subjectivity and Intersubjectivity in Psychiatric Diagnosis: Fuchs, T. (Heidelberg)
The Influence of Comorbid Personality Disorder and Neuroticism on Treatment Outcome in First Episode Depression: Bock, C.; Buhl, J.D.; Vinberg, M.; Gether, U.; Kessing, L.V. (Copenhagen)
Music = Substantial Part of the Czech Soul

Prague 2012
World Psychiatric Association
International Congress 2012
Focusing on Access, Quality and Humane Care
Prague Congress Center, Czech Republic
October 17–21, 2012

www.wpaic2012.org

Congress Secretariat: GUARANT International
Tel: +420 284 001 444, e-mail: wpaic2012@guarant.cz
The biological approach to behavior and mental disorders

Neuropsychobiology
International Journal of Experimental and Clinical Research in Biological Psychiatry, Pharmacopsychiatry, Biological Psychology/Pharmacopsychology and Pharmacoelectroencephalography

Editors
W. Strik, Bern

Selected contributions:
- Lack of Association between Testosterone and Suicide Attempts: Perez-Diaz, M.; Newmark, R.; Buchsbaum, M.S.
- Lithium’s Emerging Role in the Treatment of Refractory Major Depressive Episodes: Augmentation of Antidepressants: Adli, M.
- Computer-Assisted Sleep Classification according to the Standard of the American Academy of Sleep Medicine: Validation Study of the AASM Version of the Somnolyzer 24×7: Bauer, M.; Lopez-Castroman, J.; de Leon, J.

More information at www.karger.com/np

Permission to View and Subscription Access to Full Text

Full Table of Contents

Full Editorial Board
Free Abstracts and Selected Articles
Available online

Full Text Access

Pay-per-View and Subscriber Services
www.karger.com/nps

More information at www.karger.com/np

Bridging the gaps between medicine, ethics, philosophy and religion

Knowing One’s Medical Fate in Advance
Challenges for Diagnosis and Treatment, Philosophy, Ethics and Religion

Editors
Georg Pfleiderer
Manuel Battegay
Klaus Lindpaintner

Contents

Introduction: Pfleiderer, G.; Battegay, M.; Lindpaintner, K.

Medical Perspectives
- Evolving Therapy and Prognosis in HIV: – How Knowing One’s Medical Fate in Advance Can Change Dramatically: Battegay, M.
- Related to Human Cognition: Is Personalization Feasible and Desirable?: Battegay, M.

Ethical and Juridical Perspectives
- Ethical Decision-Making on Genetic Testing: Emerging Challenges: Lindpaintner, K.
- Predictive Medicine – Changes in Our View of Ourselves and Others: Braher, M.
- Current Challenges for the Law: Disclosure Dilemmas in Predictive Medicine: Don, B.S.

Religious Perspectives
- Fate and Judaism: Philosophical and Clinical Aspects: Braher, M.
- Karma, Contingency, and the Point of No Return: Predictive Medicine and Buddhist Perspectives: Schiene, J.

Author Index
Subject Index

KARGER

Modern medicine is now in a position to make advanced progresses that chart the entire course of illness and recovery. Paradoxically, this is coupled with a new dimension of uncertainty for the patient, i.e. coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take in this novel environment, renowned experts in this field discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epidemiological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g. the promise of a better death.

This publication aims to bridge the different fields dealing with this area by addressing the challenges faced and encouraging dialogue. It will be of interest to all readers who deal with ethical problems of prognosis, particularly in medicine, as well as to theologians and sociologists. This is coupled with a new dimension of uncertainty for the patient, i.e. coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take in this novel environment, renowned experts in this field discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epidemiological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g. the promise of a better death.
153 Illicit Drug Use in the Flemish Nightlife Scene between 2003 and 2009
Van Havere, T.; Lammertyn, J.; Vanderplasschen, W. (Ghent); Bellis, M. (Liverpool); Rosiers, J. (Brussels); Broekaert, E. (Ghent)

161 Association of a Genetic Polymorphism of the Alcohol-Metabolizing Enzyme ADH1C with Alcohol Dependence: Results of a Case-Control Study
Kortunay, S.; Köeleer, A.; Özdemir, F.; Atalay, E.O. (Denizli)

167 Co-Occurrence of Addictive Behaviours: Personality Factors Related to Substance Use, Gambling and Computer Gaming
Walther, B.; Morgenstern, M.; Hanewinkel, R. (Kiel)

175 On-Site Drugs of Abuse Urinary Screening Tests for the Management of Opiate-Addicted Patients: A Survey among French General Practitioners

184 Differential Profiles of Crack Users in Respondent-Driven and Institutional Samples: A Three-Site Comparison
Oteo Pérez, A.; Benschop, A.; Korf, D.J. (Amsterdam)

193 Validation of the Cannabis Abuse Screening Test in a Sample of Cannabis Inpatients
Legleye, S. (Paris/Saint-Denis); Kraus, I. (Munich/Stockholm); Piontek, D. (Munich); Phan, O.; Joaillier, C. (Paris)

201 Role of Two Clusters of Male Alcoholics in Treatment Retention
Baltieri, D.A.; Corêa Filho, J.M. (São Paulo)